LOG IN/REGISTER >
FORWARD TO A COLLEAGUE >
INDICATION/SAFETY INFORMATION >

Glossary of terms

This glossary of terms contains general descriptions that are used in discussing Medicare coverage and reimbursement. Private payers may use other terms or define these terms differently. Please consult the Centers for Medicare & Medicaid Services (CMS) or other payers for comprehensive definitions and requirements relating to coding, coverage, and reimbursement for items and services.

APC: Ambulatory Payment Classification. Under Medicare's Hospital Outpatient Prospective Payment System (HOPPS), items and services are assigned to payment categories called Ambulatory Payment Classifications or APCs. Current Procedural Terminology (CPT®*) and Healthcare Common Procedural Coding System (HCPCS) codes are grouped into APCs on the basis of clinical characteristics and the resources required to provide the particular service.

CC: Complications and comorbidities (CCs) are diagnosis codes used by Medicare to assign individual cases to MS-DRGs based on severity of illness.

Carrier: Carriers are private insurance companies that serve as CMS's agent in adjudicating and processing claims for payment under Medicare Part B. Thus, Medicare Carriers make coverage and payment decisions regarding items or services related to physician and supplier services.

AMA CPT®* Code: American Medical Association (AMA) Current Procedural Terminology (CPT®*) codes provide a uniform language for healthcare professionals, including physicians, physician assistants, and nurse practitioners, to bill their services to payers. CPT® codes are recorded on claim forms and submitted to payers to facilitate payment for the services or procedures performed.

Fiscal intermediary: Fiscal intermediaries (FIs) are private insurance companies that serve as CMS's agent in adjudicating and processing claims for services covered and paid under Medicare Part A.

HCPCS code: Healthcare Common Procedural Coding System (HCPCS) codes are used by all payers and describe certain services, supplies, drugs, and durable medical equipment. HCPCS J codes are typically used to describe drugs and biologics.

HOPPS: Hospital Outpatient Prospective Payment System. Medicare prospective payment system that assigns hospital outpatient payments to Ambulatory Payment Classifications or APCs. CPT® and HCPCS codes are grouped into APCs on the basis of clinical characteristics and the resources required to provide the particular service.

ICD-9-CM code: International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes are used to designate specific patient diagnoses. ICD-9-CM procedure codes are used to designate specific patient procedures in the hospital inpatient setting.

ICD-9 V codes: Supplementary ICD-9 diagnosis codes used to report factors, other than a disease or injury, influencing health status and contact with health services.

Inpatient setting: Setting of care in which items and services are furnished to a patient admitted to a hospital for at least an overnight stay.

IPPS: Hospital Inpatient Prospective Payment System (IPPS). Under the IPPS system, each Medicare hospital inpatient stay is assigned to a Medicare severity diagnosis-related group (MS-DRG) based on the patient's characteristics and the procedures performed during his or her inpatient stay. Medicare then pays the hospital a prospectively-determined amount defined by the MS-DRG.

MAC: Medicare administrative contractors (MACs) will replace FIs, carriers, and Durable Medical Equipment Regional Carriers by 2011. The new MACs will assume all Medicare coverage and payment functions of the current Part A FIs and Part B carriers.

MCC: Major complications and comorbidities (MCCs) are diagnosis codes used by Medicare to assign individual cases to MS-DRGs based on severity of illness.

MS-DRG: Medicare severity diagnosis-related group. Medicare payment grouping for inpatient hospitalizations incorporating disease severity, as indicated by MCCs or CCs (see above). Medicare inpatient claims are assigned to an MS-DRG based on the patient's characteristics and the procedures performed during his or her inpatient stay. Medicare then pays the hospital a prospectively-determined amount that is associated with the DRG selected.

Outpatient setting: Setting of care in which medical and other services are provided by a hospital or other qualified facility to a patient within a 24-hour period (ie, the patient is never admitted).

RVU: Relative value unit (RVUs) are relative weights, or values, that are intended to reflect the relative resources required to perform each procedure. The resources required to perform a procedure are divided into 3 components: a physician work component, a practice expense component, and a malpractice component.

  • *
  • CPT is a registered trademark of the American Medical Association. Current Procedural Terminology (CPT) is copyright 2007 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in CPT. The AMA assumes no liability for the data contained herein. Applicable FARS/DFARS restrictions apply to government use.

Helpful links

Genentech support

Genentech is neither affiliated with nor endorses any of the following organizations.

Professional organizations

Government sites

Acute ischemic stroke
Indication

Activase (Alteplase) is indicated for the management of acute ischemic stroke in adults for improving neurological recovery and reducing the incidence of disability. Treatment should only be initiated within 3 hours after the onset of stroke symptoms, and after exclusion of intracranial hemorrhage by a cranial computerized tomography (CT) scan or other diagnostic imaging method sensitive for the presence of hemorrhage (see CONTRAINDICATIONS).

Safety Information
Activase therapy in patients with AIS is contraindicated in certain situations (eg, suspicion of subarachnoid hemorrhage on pretreatment evaluation, recent (within 3 months) intracranial or intraspinal surgery, history of intracranial hemorrhage, uncontrolled hypertension at time of treatment, active internal bleeding, known bleeding diathesis (eg, current use of oral anticoagulants, administration of heparin within 48 hours of onset of stroke, platelet count <100,000) (see CONTRAINDICATIONS for full list).

The most common complication during Activase therapy is bleeding. Should serious bleeding in a critical location (intracranial, gastrointestinal, retroperitoneal, pericardial) occur, Activase therapy should be discontinued immediately. Death and permanent disability are not uncommonly reported in patients who have experienced stroke (including intracranial bleeding) and other serious bleeding episodes.

The risks of Activase therapy may be increased and should be weighed against the anticipated benefits in certain conditions. [See WARNINGS in full prescribing information].

  • Patients with severe neurological deficit (eg, NIHSS >22) at presentation. There is an increased risk of intracranial hemorrhage in these patients.
  • Patients with major early infarct signs on a computerized cranial tomography (CT) scan (eg, substantial edema, mass effect, or midline shift).

Treatment of patients with minor neurological deficit or with rapidly improving symptoms is not recommended.

Orolingual angioedema has been observed in postmarketing experience in patients treated with Activase for AIS. Patients should be monitored during and for several hours after infusion for signs of orolingual angioedema.

Pulmonary embolism
Indication

Activase (Alteplase) is indicated in the management of acute massive pulmonary embolism (PE) in adults: (1) for the lysis of acute pulmonary emboli, defined as obstruction of blood flow to a lobe or multiple segments of the lungs; (2) for the lysis of pulmonary emboli accompanied by unstable hemodynamics, eg, failure to maintain blood pressure without supportive measures. The diagnosis should be confirmed by objective means, such as pulmonary angiography or noninvasive procedures such as lung scanning.

Safety Information
Activase therapy in patients with pulmonary embolism (PE) is contraindicated in certain situations because of an increased risk of bleeding (eg, active internal bleeding, history of cerebrovascular accident, recent intracranial or intraspinal surgery or trauma, severe uncontrolled hypertension) [See CONTRAINDICATIONS in the full prescribing information].

The most common complication during Activase therapy is bleeding. Should serious bleeding in a critical location (intracranial, gastrointestinal, retroperitoneal, pericardial) occur, Activase therapy should be discontinued immediately, along with any concomitant therapy with heparin.

The risks of Activase therapy for all approved indications may be increased and should be weighed against the anticipated benefits in certain conditions [See WARNINGS in full prescribing information].

Treatment of PE with Activase has not been shown to constitute adequate clinical treatment of underlying deep vein thrombosis. The possible risk of reembolization due to the lysis of underlying deep venous thrombi should be considered.

Please click here for full prescribing information.